Open AccessTrientine Hydrochloride (MAR-Trientine)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.211
Subject(s) - medicine , surgery
CADTH recommends that MAR-Trientine should be reimbursed by public drug plans for the treatment of patients with Wilson's disease if certain conditions are met.
MAR-Trientine should only be covered to treat patients who have previously tried and demonstrated intolerance to d-penicillamine.
MAR-Trientine should only be reimbursed if initiated by clinicians experienced in the management of Wilson’s disease and if the cost of MAR-Trientine is reduced.